The US CMS*has been commended by pharmaceutical company Chiron Corporation for implementing a reimbursement change on 1 October that will increase access to high-dose interleukin-2 (IL-2)

 

作者: &NA;,  

 

期刊: PharmacoEconomics & Outcomes News Weekly  （ADIS Available online 2003）
卷期: Volume &NA;, issue 433  

页码: 12-12

 

ISSN:1173-5503

 

年代: 2003

 

出版商: ADIS

 

数据来源: ADIS

 

 

返 回